GICS Sector : Healthcare
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma.2seventy bio, Inc.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Apr -16
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results
Mar -25
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why
Mar -17
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT
Mar -12
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
Mar -12
TSVT Up on Acquisition Agreement With BMY for $286 Million
Mar -11
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of 2seventy bio, Inc.
Mar -11
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Mar -11
2seventy bio's cancer treatment growth is driven by increasing cancer prevalence, rising adoption of gene therapies, and strong clinical trial results. The company's innovative pipeline, strategic partnerships, and expanding manufacturing capabilities also contribute to its 14% growth. Additionally, growing demand for personalized medicine and increasing investment in oncology research further fuel the segment's growth.
Abecma is a B-cell maturation antigen (BCMA) directed CD3 T cell stimulator, approved for the treatment of adult patients with relapsed or refractory multiple myeloma.
Breyanzi is a CD19-directed genetically modified autologous T cell immunotherapy, approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Tecartus is a CD19-directed genetically modified autologous T cell immunotherapy, approved for the treatment of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and relapsed or refractory large B-cell lymphoma.
The threat of substitutes for 2seventy bio, Inc. is moderate due to the presence of alternative biotechnology companies.
The bargaining power of customers for 2seventy bio, Inc. is low due to the company's specialized products and services.
The bargaining power of suppliers for 2seventy bio, Inc. is moderate due to the availability of multiple suppliers for raw materials and services.
The threat of new entrants for 2seventy bio, Inc. is high due to the growing demand for biotechnology products and services.
The intensity of rivalry for 2seventy bio, Inc. is high due to the presence of established competitors in the biotechnology industry.
| Value | |
|---|---|
| Debt Weight | 50.13% |
| Debt Cost | 3.95% |
| Equity Weight | 49.87% |
| Equity Cost | 13.25% |
| WACC | 8.59% |
| Leverage | 100.54% |
Value: 8.0
Growth: 4.2
Quality: 4.6
Yield: 0.0
Momentum: 6.5
Volatility: 3.7
1-Year Total Return ->
Value: 7.6
Growth: 4.4
Quality: 4.4
Yield: 0.0
Momentum: 5.0
Volatility: 0.7
1-Year Total Return ->
Value: 7.0
Growth: 6.0
Quality: 3.2
Yield: 0.0
Momentum: 4.0
Volatility: 1.7
1-Year Total Return ->
Value: 9.2
Growth: 3.9
Quality: 6.0
Yield: 0.0
Momentum: 1.0
Volatility: 1.3
1-Year Total Return ->
Value: 7.6
Growth: 3.6
Quality: 5.0
Yield: 0.0
Momentum: 2.0
Volatility: 1.7
1-Year Total Return ->
Value: 7.8
Growth: 3.2
Quality: 3.5
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->